Insights from BCC Research

Computational Approaches Opening New Frontiers in Drug Discovery

Posted by Laurie L. Sullivan on Feb 26, 2018 11:00:00 AM

Drug Discovery.jpegGlobally, the rise in research expenditures, deterioration in human health conditions and the need for novel and effective therapies have boosted the demand for drug discovery tools. In just the last few years, the drug discovery and development industry has undergone a major transition, with increased calls for efficient, user-friendly and affordable products. A new study by BCC Research examines all aspects of the drug discovery process, which consumes a major portion of drug development costs. Therefore, it is imperative for companies to use technologies that offer a high probability that their future drug product will be commercially successful.

Read More

Topics: Life Sciences, Biotechnology

DNA Sequencing in the Golden Age of Biology

Posted by BCC Research Editorial on Feb 6, 2018 12:45:00 PM

On January 31, 2018, BCC Research analyst Smruti Munshi presented a Member-exclusive webinar on the future of mobile apps for DNA sequencing, and more specifically, smartphone apps used to interpret the data for both genealogical and medical applications. The technology is in a nascent stage, and the possibilities are seemingly endless. Senior Editor Chris Spivey captures the frontier-nature of DNA sequencing in his introduction, which is transcribed below. 

Read More

Topics: Life Sciences, Biotechnology, Speaker Series

Webinar Recap: 3D Cell Culture Market Growing at 36% CAGR

Posted by BCC Research Editorial on Feb 2, 2018 12:45:00 PM
robert_hunter.jpgThe market for 3D cell culture is set to revolutionize cancer treatment (both safety and efficacy), central nervous system (CNS) research and stem cell applications for drug testing and the development of regenerative medicine and cell therapy treatments.  
Read More

Topics: Life Sciences, Biotechnology, Speaker Series

Market for Enzyme Inhibitors Faces Generic Competition, Payer Pushback

Posted by Laurie L. Sullivan on Jan 16, 2018 10:00:00 AM

Enzyme_Inhibitor copy.jpgThe development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. A newly updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022. Enzyme inhibitors offer therapeutic options for myriad illnesses, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.

Read More

Topics: Life Sciences, Biotechnology